Israel

Luminera

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Allergan Aesthetics, an AbbVie Company, Acquires Innovative Luminera Dermal Filler Business

Lead Product(s): Hyaluronic Acid,Calcium Hydroxyapatite

Therapeutic Area: Dermatology Product Name: HArmonyCa

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Innovative Luminera

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition October 07, 2020

Details:

Allergan Aesthetics will acquire Luminera's full dermal filler portfolio and R&D pipeline further enhancing Allergan Aesthetics' leading dermal filler portfolio with its JUVÉDERM® collection of fillers.

Foamix Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

ISRAEL Israel

Post An Enquiry

Virtual Booth

CPhI North America Online

Participation Not Confirmed

Update your events

Menlo Therapeutics and Cutia Therapeutics ink License Agreement for AMZEEQ™ and Approved Topical Minocycline Products in Greater China

Lead Product(s): Minocycline Hydrochloride

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Cutia Therapeutics

Deal Size: $11.0 million Upfront Cash: $10.0 million

Deal Type: Licensing Agreement April 23, 2020

Details:

Cutia will have an exclusive license to obtain regulatory approval and sell AMZEEQ. Foamix is to supply Cutia with the finished licensed products for clinical and commercial use.